Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. Issue 2 (28th January 2019)

• Record Type: Journal Article
• Authors: Pennisi, Martina; Berchicci, Luigi; Miserocchi, Elisabetta; Mussetti, Alberto; Cacioppo, Viviana; David, Alessandro; Scialdone, Antonio; Lorusso, Ilaria; Modorati, Giulio; Corradini, Paolo; Montefusco, Vittorio
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 2(2019)
• Page Start: 477
• Page End: 482
• Publication Date: 2019-01-28
• Subjects: Multiple myeloma -- ocular disorders -- toxicity; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1480770
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Multiple myeloma (MM) therapy is evolving, and several new drugs are now available, extending patients' life and exposure to different compounds and toxicities. We conducted a cross-sectional observational study enrolling 93 consecutive patients on active treatment for MM, aiming to assess their ocular complications. All the patients underwent a comprehensive ophthalmic evaluation. In our cohort, prevalence of low visual acuity was in line with similar age healthy population reported in registry studies. Interestingly, we recorded a higher prevalence of lens opacities (46%) and dry eye syndrome (53%). Nevertheless, we did not find any significant association between ocular disorders and anti-myeloma treatments, even steroid therapy. This observation suggests that other factors besides treatments, such as M-protein deposition in eye structures, may have a role in developing ocular toxicities. Since MM patients are elderly patients at higher risk of age-related eye disorders, we recommend periodic ophthalmic assessment in daily practice.